This is the authors' abstract. We don't add key points for this paper.
I was the Chairman of the panel (“consensus panel”), appointed by the American Association of Clinical Endocrinologists, the American Thyroid Association, and The Endocrine Society, that was charged with developing evidencebased practice guidelines for the diagnosis and management of subclinical thyroid disease (1). I appreciate the opportunity to review, before publication, and to comment on the paper by Gharib et al. (2) in this issue of JCEM. This paper is a joint statement from the above societies/associations that presents opinions that are different from several recommendations in the evidence-based report (1). In this note, I will comment on the most important differences between the opinions expressed by Gharib et al. (2) and the recommendations published in the “Scientific Review” and “Clinical Applications” papers (1, 3).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Martin I. Surks (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: